NCT06465264View on ClinicalTrials.gov

To Assess Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil

PHASE3CompletedINTERVENTIONAL
Enrollment

499

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

August 16, 2022

Study Completion Date

February 24, 2023

Conditions
Essential Hypertension
Interventions
DRUG

Allisartan Isoproxil/Amlodipine group 1

"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."

DRUG

Amlodipine group 1

"One Amlodipine (5 mg) tablet and one placebo of Allisartan Isoproxil/Amlodipine during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."

DRUG

Allisartan Isoproxil/Amlodipine group 2

"One Allisartan Isoproxil/Amlodipine (240 mg/5 mg) tablet and one placebo of Allisartan Isoproxil (240 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."

DRUG

Allisartan Isoproxil group 2

"One Allisartan Isoproxil (240 mg) and one placebo of Allisartan Isoproxil/Amlodipine (240 mg/5 mg) during the double-blind period (Week 4\~Week 16).~One Allisartan Isoproxil/Amlodipine(240 mg/5 mg) tablet during the open-label period(Week 16\~ Week 56) once daily."

Trial Locations (1)

100020

Beijing Chaoyang Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY